Vestmark Advisory Solutions Inc. Makes New $4.33 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Vestmark Advisory Solutions Inc. bought a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 77,409 shares of the company’s stock, valued at approximately $4,332,000. Vestmark Advisory Solutions Inc. owned approximately 0.07% of 10x Genomics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TXG. UMB Bank n.a. boosted its holdings in shares of 10x Genomics by 51.6% in the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock valued at $44,000 after buying an additional 266 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $66,000. Van ECK Associates Corp boosted its holdings in shares of 10x Genomics by 23.4% in the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock valued at $107,000 after buying an additional 362 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of 10x Genomics in the 3rd quarter valued at about $146,000. Finally, Powell Investment Advisors LLC bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $200,000. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of 10x Genomics from $30.00 to $26.00 and set a “sell” rating on the stock in a report on Wednesday. Barclays decreased their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. UBS Group lowered their target price on shares of 10x Genomics from $52.00 to $30.00 and set a “neutral” rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. Finally, TD Cowen cut shares of 10x Genomics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $57.00 to $32.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.50.

10x Genomics Trading Up 4.5 %

NASDAQ TXG traded up $1.19 on Friday, hitting $27.48. 2,385,262 shares of the company’s stock traded hands, compared to its average volume of 1,968,632. 10x Genomics, Inc. has a 1-year low of $24.60 and a 1-year high of $63.57. The firm’s 50-day moving average price is $35.81 and its two-hundred day moving average price is $42.10. The firm has a market capitalization of $3.27 billion, a PE ratio of -12.32 and a beta of 1.94.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The business had revenue of $141.01 million during the quarter, compared to analysts’ expectations of $142.24 million. During the same period in the previous year, the business posted ($0.44) EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, research analysts anticipate that 10x Genomics, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at approximately $42,367,020.93. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now owns 855,381 shares of the company’s stock, valued at approximately $42,367,020.93. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the completion of the sale, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The disclosure for this sale can be found here. Insiders sold a total of 12,959 shares of company stock worth $592,806 in the last three months. Company insiders own 10.65% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.